Aryl-quinoline-4-carbonyl hydrazone bearing different 2-methoxyphenoxyacetamides as potent α-glucosidase inhibitors; molecular dynamics, kinetic and structure-activity relationship studies

Sci Rep. 2024 Jan 3;14(1):388. doi: 10.1038/s41598-023-50395-8.

Abstract

Regarding the important role of α-glucosidase enzyme in the management of type 2 diabetes mellitus, the current study was established to design and synthesize aryl-quinoline-4-carbonyl hydrazone bearing different 2-methoxyphenoxyacetamide (11a-o) and the structure of all derivatives was confirmed through various techniques including IR, 1H-NMR, 13C-NMR and elemental analysis. Next, the α-glucosidase inhibitory potentials of all derivatives were evaluated, and all compounds displayed potent inhibition with IC50 values in the range of 26.0 ± 0.8-459.8 ± 1.5 µM as compared to acarbose used as control, except 11f and 11l. Additionally, in silico-induced fit docking and molecular dynamics studies were performed to further investigate the interaction, orientation, and conformation of the newly synthesized compounds over the active site of α-glucosidase.

MeSH terms

  • Diabetes Mellitus, Type 2*
  • Glycoside Hydrolase Inhibitors / chemistry
  • Glycoside Hydrolase Inhibitors / pharmacology
  • Humans
  • Hydrazones / chemistry
  • Hydrazones / pharmacology
  • Kinetics
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Molecular Structure
  • Quinolines* / chemistry
  • Saccharomyces cerevisiae / metabolism
  • Structure-Activity Relationship
  • alpha-Glucosidases / metabolism

Substances

  • Glycoside Hydrolase Inhibitors
  • alpha-Glucosidases
  • Hydrazones
  • Quinolines